Table 1.
Clinical trials investigating immunogenic cell stress mediated by chemotherapy.
| Clinical Trial | Trial Title | Conditions | Treatment | Phases |
|---|---|---|---|---|
| NCT03801304 | Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer | Non-small-cell lung cancer | Atezolizumab Vinorelbine |
Phase II |
| NCT04159818 | Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients (TONIC-2) | Metastatic breast cancer | Nivolumab Cisplatin Low-dose doxorubicin |
Phase II |
| NCT04043195 | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC | Advanced non-small cell lung cancer (NSCLC) | Oxaliplatin Nivolumab Ipilimumab |
Phase I Phase II |
| NCT04463368 | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases (SCANDIUM II) |
Uveal melanoma Liver metastases |
Melphalan Ipilimumab Nivolumab |
Phase I |
| NCT04072263 | Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer (OVACURE) | Recurrent ovarian cancer | Tumor-infiltrating lymphocytes Interferon alfa 2A Carboplatin Paclitaxel |
Phase I Phase II |
| NCT04262687 | Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer with High Immune Infiltrate (POCHI) | Metastatic colorectal cancer High immune infiltrate Microsatellite stable (MSS) |
Capecitabine Oxaliplatin Bevacizumab Pembrolizumab |
Phase II |
| NCT05420584 | Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI) |
Rectal neoplasms | Tislelizumab Capecitabine Oxaliplatin |
Phase II |
| NCT04989218 | Durvalumab and Tremelimumab with Platinum-based Chemo- therapy in Intrahepatic Cholangiocarcinoma (ICC) |
Cholangiocarcinoma | Gemcitabine Cisplatin Tremelimumab Durvalumab |
Phase I Phase II |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | Breast cancer Small cell and non-small cell lung cancer Triple negative breast cancer Gastric cancer Esophageal adenocarcinoma Gastric junction adeno- carcinoma Esophageal squamous cell carcinoma Head and neck cancer Squamous cell carcinoma of oral cavity Squamous cell carcinoma of larynx Squamous cell carcinoma of nasopharynx Squamous cell carcinoma of other specified sites of skin Carcinoma of unknown primary Bladder cancer Malignant melanoma |
RAPA-201 cells Carboplatin Paclitaxel |
Phase II |
| NCT05307198 | Rectal Artery Infusion Chemotherapy Combined with Anti-PD1 Antibody for MSS LARC (RAIC) | Rectal neoplasms | Capecitabine Oxaliplatin Sintilimab |
Phase II |
| NCT02499367 | Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients (TONIC) | Breast cancer | Nivolumab Radiation therapy Low dose doxorubicin Cyclophosphamide Cisplatin |
Phase II |
| NCT03409198 | Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer (ICON) | Breast cancer Hormone receptor positive tumor Metastatic breast cancer |
Ipilimumab Nivolumab Pegylated liposomal doxorubicin Cyclophosphamide |
Phase II |
| NCT03164993 | Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer (ALICE) | Breast cancer Triple-negative breast cancer |
Atezolizumab Pegylated liposomal doxorubicin Cyclophosphamide |
Phase II |
| NCT02649855 | Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer | Prostate cancer Prostate neoplasms |
PROSTVAC-V PROSTVAC-F Docetaxel |
Phase II |
PD-1: programmed cell death protein 1, RAPA-201: rapamycin-resistant T cells, PROSTVAC: vaccine targeting prostate-specific antigen.